サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1561542

胃不全麻痺治療薬市場レポート：疾患タイプ、薬剤クラス別、流通チャネル、地域別、2024年～2032年

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
胃不全麻痺治療薬市場レポート：疾患タイプ、薬剤クラス別、流通チャネル、地域別、2024年～2032年
出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の胃不全麻痺治療薬の市場の市場規模は2023年に65億米ドルに達しました。今後、IMARC Groupは、2024年から2032年の間に4.3%の成長率（CAGR）を示し、市場は2032年までに95億米ドルに達すると予測しています。糖尿病性胃不全麻痺の有病率の上昇、医薬品開発技術の進歩、ヘルスケア専門家や患者の意識の向上、医療投資の急増、臨床試験の増加、糖尿病やパーキンソン病などの慢性疾患の急増、規制当局の支援などが市場成長を後押しする要因の一部です。

胃不全麻痺治療薬の市場分析：

  • 主な市場促進要因：糖尿病有病率の増加が胃不全麻痺の有病率を大幅に押し上げ、市場成長の原動力となっています。また、診断ソリューションの改善により、患者の早期発見が可能になったことも、市場の成長を後押ししています。さらに、胃不全麻痺にかかりやすい老年人口が増加していることも、市場を前進させる要因となっています。これに伴い、先進的なドラッグデリバリーシステムの使用が増加し、ヘルスケアプロバイダーや患者の間で胃不全麻痺に対する認識が高まっていることが、市場の成長を促進しています。さらに、特に発展途上地域におけるヘルスケアインフラの急速な拡大や、胃腸研究に対する政府の取り組みや資金援助が、前向きな胃不全麻痺治療薬の市場見通しを生み出しています。
  • 主要市場動向：個別化医療への嗜好の変化は、主要な市場動向の1つです。さらに、新規治療開発のペースを高めるために、創薬における機械学習（ML）と人工知能（AI）の統合が市場の成長を後押ししています。さらに、低侵襲手術（MIS）に対する需要の高まりが、高度なドラッグデリバリーシステムの使用に拍車をかけており、これも市場拡大を後押しする要因となっています。さらに、外来治療や在宅治療が重視されるようになり、胃不全麻痺研究への投資が急増していることも、市場の成長を促進しています。
  • 地理的動向：北米は、糖尿病有病率の急増、先進治療の継続的開拓、強固なヘルスケアインフラの存在により、最大の市場シェアを占めています。胃不全麻痺治療薬の市場予測によると、欧州もドイツ、英国、フランスなどの主要市場プレイヤーの存在に支えられ、かなりの市場シェアを占めています。アジア太平洋では、ヘルスケア投資の増加、患者数の増加、胃不全麻痺に関する認知度の向上が市場成長を促進しています。
  • 競合情勢：胃不全麻痺治療薬業界の主な市場プレイヤーには、Abbott Laboratories、Abbvie Inc.、AstraZeneca Plc、Bausch Health Companies Inc.、Becton Dickinson and Company、Boston Scientific Corporation、Evoke Pharma、Medtronic plc、Neurogastrx Inc.、Sanofi S.A.、武田薬品工業、Theravance Biopharmaなどがいます。
  • 課題と機会：市場概要によると、胃不全麻痺治療薬の市場は主に病態生理の限られた理解と現在利用可能な薬に関連する副作用によって抑制されています。しかし、バイオテクノロジーとゲノミクスの急速な進歩、新たな標的治療の市場開拓は、市場拡大の有利な機会をもたらしています。さらに、胃不全麻痺の診断が向上し、世界中で糖尿病患者が急増していることも、市場の成長を刺激しています。

胃不全麻痺治療薬の市場傾向：

胃不全麻痺の有病率の増加

特に糖尿病患者における胃不全麻痺の有病率の上昇が市場成長を加速させています。2021年のインドの20～79歳の糖尿病患者は約7,490万人で、2045年には1億2,490万人に達すると予測されています。さらに、糖尿病患者の増加により、効率的な治療と管理の必要性が急増しており、これが市場成長に大きな推進力を与えています。さらに、主な製薬会社は新しい標的治療の開発に積極的に取り組んでおり、これが市場の見通しをさらに明るいものにしています。

医薬品開発技術の進歩

パイプラインにある製品数の増加と新製品バリエーションの開発が市場開拓を後押ししています。さらに、胃不全麻痺治療薬の有効性と安全性を向上させるための医薬品研究開発（R&D）への投資が急増し、市場の成長を後押ししています。胃不全麻痺治療薬の市場ハイスループット・スクリーニング、計算医学、個別化医療の出現により、潜在的な候補薬を正確かつ迅速に同定できるようになるなど、最近の機会が市場成長に弾みをつけています。これとは別に、徐放性製剤や新規ドラッグデリバリー機構などのドラッグデリバリーシステムの進歩が、薬剤の効率的な投与と吸収を実現し、市場成長を後押ししています。

ヘルスケア専門家と患者の意識の高まり

胃不全麻痺に関するヘルスケア専門家と患者の意識の高まりは、市場の成長を著しく促進しています。胃不全麻痺の患者は、その後の認知度の向上により、より正確に診断されるようになり、それがさらに市場成長に大きな推進力を与えています。さらに、消化器専門医のようなヘルスケア専門家は、症状をより鋭く認識するようになり、胃不全麻痺をより早く認識し、より良い患者ケアにつながります。さらに、胃不全麻痺の症状や治療に対する患者の意識の高まりや、新しい治療オプションの利用可能性が、胃不全麻痺治療薬の需要を促進しています。

本レポートで扱う主な質問

  • 2023年における胃不全麻痺治療薬の市場の世界市場規模は？
  • 2024-2032年における胃不全麻痺治療薬の市場の世界市場成長率は？
  • 世界の胃不全麻痺治療薬の市場に対するCOVID-19の影響は？
  • 世界の胃不全麻痺治療薬の市場を牽引する主な要因は何か
  • 胃不全麻痺治療薬の市場の疾病タイプ別内訳は？
  • 胃不全麻痺治療薬の市場の薬剤クラス別内訳は？
  • 世界の胃不全麻痺治療薬の市場の販売チャネル別の内訳は？
  • 世界の胃不全麻痺治療薬の市場における主要地域はどこか
  • 世界の胃不全麻痺治療薬の市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の胃不全麻痺治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：疾患別

  • 糖尿病性胃不全麻痺
    • 市場動向
    • 市場予測
  • 特発性胃不全麻痺
    • 市場動向
    • 市場予測
  • 術後胃不全麻痺
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • 消化管運動促進剤
    • 市場動向
    • 市場予測
  • 制吐剤
    • 市場動向
    • 市場予測
  • ボツリヌス毒素注射
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院と診療所
    • 市場動向
    • 市場予測
  • 薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
図表

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players
目次
Product Code: SR112024A4608

The global gastroparesis drugs market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth.

Gastroparesis Drugs Market Analysis:

  • Major Market Drivers: The increasing prevalence of diabetes has considerably boosted the prevalence of gastroparesis, which is fueling the market growth. This is further supported by the improvements in diagnosis solutions, which enable early disease identification among patients. Moreover, the escalating geriatric population susceptible to gastroparesis is another factor propelling the market forward. In line with this, the growing use of advanced drug delivery systems and surging awareness about gastroparesis among healthcare providers and patients are facilitating the market growth. Furthermore, the rapid expansion of healthcare infrastructure, especially in developing regions, and government initiatives and funding for gastrointestinal research are creating a positive gastroparesis drugs market outlook.
  • Key Market Trends: The shifting preference toward personalized medicine is one of the primary market trends. Moreover, the integration of machine learning (ML) and artificial intelligence (AI) in drug discovery to boost the pace of novel therapy development is bolstering the market growth. Additionally, the increasing demand for minimally invasive surgery (MIS) has fueled the use of advanced drug delivery systems, which is another factor driving market expansion. Furthermore, the escalating emphasis on outpatient care and home-based treatments and burgeoning investments in gastroparesis research are facilitating the market growth.
  • Geographical Trends: North America holds the largest market share due to the burgeoning prevalence of diabetes, the continuous development of advanced treatments, and the presence of robust healthcare infrastructure. As per the gastroparesis drugs market forecast, Europe also holds a considerable market share backed by the presence of key market players in countries, such as Germany, the UK, and France. In the Asia Pacific, rising healthcare investments, growing patient numbers, and increasing awareness regarding gastroparesis are fostering the market growth.
  • Competitive Landscape: Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Theravance Biopharma, among many others.
  • Challenges and Opportunities: As per the market overview, the gastroparesis drugs market is primarily restrained by the limited understanding of pathophysiology and the side effects associated with currently available medications. However, the rapid advancement in biotechnology and genomics and the development of new targeted therapies are presenting lucrative opportunities for market expansion. Furthermore, the improving diagnosis of gastroparesis and burgeoning cases of diabetes across the globe are stimulating the market growth.

Gastroparesis Drugs Market Trends:

Increasing Prevalence of Gastroparesis

The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.

Advancements in Drug Development Technologies

The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.

Rising Awareness Among Healthcare Professionals and Patients

The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.

Gastroparesis Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on disease type, drug class, and distribution channel.

Breakup by Disease Type:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Idiopathic gastroparesis accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others. According to the report, idiopathic gastroparesis represented the largest segment.

The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.

Breakup by Drug Class:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Prokinetic agents hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes prokinetic agents, antiemetic agents, and botulinum toxin injections. According to the report, prokinetic agents accounted for the largest market share.

The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Pharmacies
  • Online Stores

Hospitals and clinics represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospitals and clinics, pharmacies, and online stores. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest gastroparesis drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.

The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The key gastroparesis drugs companies are actively engaged in several strategic initiatives to advance their position and address the growing demand for effective treatments. They are investing heavily in research and development (R&D) to discover and develop new drugs that target the underlying mechanisms of gastroparesis more effectively. These companies are focusing on innovative drug formulations, including extended-release and novel delivery systems, to enhance the efficacy and patient compliance of treatments. Collaborations and partnerships with research institutions and academic organizations are being pursued to leverage external expertise and resources, which accelerates the development of new therapies. Additionally, leading players are expanding their clinical trial programs to test new drug candidates and gather crucial data to support regulatory approvals. They are also actively seeking regulatory support to expedite the approval process for new treatments, aiming to bring innovative solutions to market more quickly.

Gastroparesis Drugs Market News:

  • In 2023, Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced the FDA Orange Book listing of a new patent for their drug GIMOTI. The patent, titled "Nasal Formulations of Metoclopramide," extends GIMOTI's patent protection through 2029. This addition marks the fourth patent listed for GIMOTI, enhancing its intellectual property portfolio, and securing its position in the market for treating diabetic gastroparesis.
  • In 2023, Enterra Medical announced that its Enterra(R) II System received FDA approval for MR Conditional use. This advanced treatment for gastroparesis, which includes the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, now allows patients to undergo MRI scans of the head and extremities under specific conditions.

Key Questions Answered in This Report

  • 1. What was the size of the global gastroparesis drugs market in 2023?
  • 2. What is the expected growth rate of the global gastroparesis drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4. What are the key factors driving the global gastroparesis drugs market?
  • 5. What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6. What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7. What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8. What are the key regions in the global gastroparesis drugs market?
  • 9. Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis